Sweden's Vimian Q2 revenue, adjusted EBITA beat expectations

Vimian AB

17/07/2026 06:56

Overview
Sweden animal health firm's Q2 revenue rose 17%, beating analyst expectations
Adjusted EBITA for Q2 rose 17% and beat analyst expectations
Adjusted EBITA margin improved, mainly due to MedTech segment profitability

Outlook
Company did not provide specific guidance or outlook for the current or future periods in the press release

Result Drivers
MEDTECH PROFITABILITY - Adjusted EBITA margin improvement mainly driven by higher profitability in MedTech segment
SEGMENT PERFORMANCE - Strong performance across all four segments contributed to adjusted EBITA growth            Company press release: ID:nMFN5XcF8X

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
EUR 121.60 mln
EUR 118.03 mln (5 Analysts)
Q2 Net Income
 
EUR 8.80 mln
 
Q2 Adjusted EBITA
Beat
EUR 29.70 mln
EUR 29.05 mln (4 Analysts)
Q2 Adjusted EBITA Margin
 
24.50%
 
Q2 Operating Profit
 
EUR 22.30 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Vimian Group AB is SEK37.00, about 13.7% above its July 16 closing price of SEK32.55
The stock recently traded at 24 times the next 12-month earnings vs. a P/E of 23 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)